



**Date:** January 19, 2018

**Administrative Circular:** 2018:02

**ATTN:** Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual,  
Chapter 2: Immunization, Part 2-Immunization of Special Populations, Part 4-  
Biological Products & Part 5-Adverse Events Following Immunization**

**Part 2-Immunization of Special Populations**

**Chronic Kidney Disease**

- The BC Renal Agency Hepatitis B Guidelines document date has been updated to November 2017.

**Please remove page numbers: 1-3 dated October 2017  
Please add new page numbers: 1-3 dated January 2018**

**Individuals with Neurological Conditions**

- Pneumococcal vaccine has been added to the table of “Recommended vaccines for individuals with pre-existing neurological conditions”, as pneumococcal polysaccharide and/or conjugate vaccine (depending on age) are recommended for those with chronic neurological conditions that may impair clearance of oral secretions.
- Content related to Guillain-Barré syndrome (GBS) and Menactra® has been removed as GBS is no longer a contraindication for receipt of Menactra®.

**Please remove page numbers: 1-2 dated January 2009  
Please add new page numbers: 1-2 dated January 2018**

### **Health Care Workers**

- Content regarding acceptable proof of immunity to hepatitis B has been added for clarity, indicating that laboratory testing for anti-HBs in the absence of a documented complete vaccine series is not acceptable. A hyperlink has been added to *Part 1-Immunization Schedules, 1.1 Consideration of Immunization History* for more information regarding adequate proof of vaccination history.

**Please remove page numbers: 1-3 dated January 2016  
Please add new page numbers: 1-3 dated January 2018**

### **Part 4-Biological Products**

#### **Tetanus-Diphtheria-Acellular Pertussis (ADACEL® and BOOSTRIX®)**

- INDICATIONS has been updated to include “booster dose for individuals 4 years of age and older who are up-to-date for polio immunization”. Associated footnote D has been added, indicating that Tdap is not indicated for primary immunization of children less than 7 years of age.

**Please remove page numbers: 1-3 dated January 2016  
Please add new page numbers: 1-3 dated January 2018**

#### **Hepatitis B Vaccine (ENGERIX®-B)**

- Content under the BOOSTER DOSES and SEROLOGICAL TESTING subsections has been revised to include the updated subsection titles and hyperlink to the updated *Communicable Disease Control Manual, Chapter 1: Hepatitis B* guidelines.

**Please remove page numbers: 1-2 dated January 2017  
Please add new page numbers: 1-2 dated January 2018**

#### **Hepatitis B Vaccine (RECOMBIVAX HB®)**

- Content under the BOOSTER DOSES and SEROLOGICAL TESTING subsections has been revised to include the updated subsection titles and hyperlink to the updated *Communicable Disease Control Manual, Chapter 1: Hepatitis B* guidelines.
- SPECIAL CONSIDERATIONS has been updated to remove the content related to a 0.5 mL (5mcg) dose representing the “Hepatitis B Vaccine Higher Dose” for children less than 11 years of age, as this is now the standard dose for this age cohort.

**Please remove page numbers: 1-2 dated January 2017  
Please add new page numbers: 1-2 dated January 2018**

Page 2 of 4

### **Hepatitis B Higher Dose Schedule**

- Footnote C has been revised to indicate that the RECOMBIVAX HB® Dialysis Formulation (40 mcg/1 mL) may be used for kidney transplant candidates and recipients.

**Please remove page number: 1 dated October 2017  
Please add new page number: 1 dated January 2018**

### **Hepatitis B Vaccine Program for Chronic Kidney Disease Clients**

- The BC Renal Agency Hepatitis B Guidelines document date has been updated to November 2017.

**Please remove page number: 1 dated October 2017  
Please add new page number: 1 dated January 2018**

### **Measles, Mumps, Rubella (MMR II® and PRIORIX®)**

- The following indication has been revised for clarity: “Infants from 6-11 months of age who are traveling to *measles* endemic areas or who are identified as contacts of a measles case”.

**Please remove page numbers: 1-4 dated January 2016  
Please add new page numbers: 1-4 dated January 2018**

### **Tetanus Immune Globulin (Tig) HyperTET®S/D**

- DOSES AND SCHEDULE has been revised to remove content regarding the consideration of a 2<sup>nd</sup> dose of Tig 30 days after the 1<sup>st</sup> dose. A 2<sup>nd</sup> dose is not recommended as the half-life of Tig is 23 days, and extends beyond the 21 day incubation period for tetanus.

**Please remove page numbers: 1-2 dated September 2015  
Please add new page numbers: 1-2 dated January 2018**

### **Part 5-Adverse Events Following Immunization**

- The temporal criteria for “intussusception or hematochezia” following receipt of rotavirus vaccine has been corrected from “0-42 hours” to 0-42 days”.

**Please remove page number: 10 dated November 2016  
Please add new page number: 10 dated January 2018**

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: [christine.halpert@bccdc.ca](mailto:christine.halpert@bccdc.ca)) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: [stephanie.meier@bccdc.ca](mailto:stephanie.meier@bccdc.ca)).

Sincerely,



Monika Naus MD MHS Sc FRCPC FACPM  
Medical Director  
Immunization Programs and Vaccine Preventable Diseases Service  
BC Centre for Disease Control

pc:

BC Ministry of Health:  
Dr. Perry Kendall  
Provincial Health Officer

Dr. Bonnie Henry  
Deputy Provincial Health Officer

Dr. Mark Tyndall  
Executive Medical Director  
BC Centre for Disease Control, and  
Deputy Provincial Health Officer

Craig Thompson  
Director, Provincial Immunization Services

Brian Sagar  
Acting Executive Director, Public Health Services & Office of Aboriginal Health